Sanofi & Weill Cornell Medical College to Discover New Anti-infectives

Under the terms of the collaboration, Sanofi will provide 80,000 chemical compounds to Weill Cornell, where the compounds will be screened to assess their ability to inhibit growth of Mycobacterium tuberculosis.

Sanofi has inked a research collaboration deal with Weill Cornell Medical College to develop new anti-infectives that aim to shorten the course of treatment of tuberculosis and provide effective therapies against drug-susceptible and drug-resistant strains of TB.

Sanofi will provide 80,000 chemical compounds to Dr. Carl Nathan's laboratory at Weill Cornell, where the compounds will be screened to assess their ability to inhibit growth of Mycobacterium tuberculosis. Weill Cornell has secured funding for the screening activities conducted by Dr. Nathan's team from the Bill & Melinda Gates Foundation. Sanofi and Weill Cornell will jointly determine if any compounds screened through the collaboration should be brought forward for optimization and further development.